PolyPid Ltd. (PYPD)

NASDAQ: PYPD · IEX Real-Time Price · USD
3.980
-0.080 (-1.97%)
At close: Jun 24, 2024, 2:27 PM
4.030
+0.050 (1.26%)
After-hours: Jun 24, 2024, 4:37 PM EDT
-1.97%
Market Cap 6.58M
Revenue (ttm) n/a
Net Income (ttm) -23.87M
Shares Out 1.65M
EPS (ttm) 16.93
PE Ratio 0.24
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,952
Open 4.000
Previous Close 4.060
Day's Range 3.850 - 4.000
52-Week Range 3.566 - 12.300
Beta 1.32
Analysts Buy
Price Target 12.00 (+201.51%)
Earnings Date Aug 7, 2024

About PYPD

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was i... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 26, 2020
Employees 59
Stock Exchange NASDAQ
Ticker Symbol PYPD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for PYPD stock is "Buy." The 12-month stock price forecast is $12.0, which is an increase of 201.51% from the latest price.

Price Target
$12.0
(201.51% upside)
Analyst Consensus: Buy
Stock Forecasts

News

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

PETACH TIKVA, Israel, June 10, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...

14 days ago - GlobeNewsWire

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100  for the Prevention of Abdominal Colorectal Surgical Site Infections

6 weeks ago - GlobeNewsWire

PolyPid to Participate in Citizens JMP Life Sciences Conference

PETACH TIKVA, Israel, May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced tha...

7 weeks ago - GlobeNewsWire

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results ...

7 weeks ago - GlobeNewsWire

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...

2 months ago - GlobeNewsWire

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced t...

4 months ago - GlobeNewsWire

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100  for the Prevention of Abdominal Colorectal Surgical Site Infections

4 months ago - GlobeNewsWire

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Rec...

4 months ago - GlobeNewsWire

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...

5 months ago - GlobeNewsWire

PolyPid Announces Private Placement for $16 Million in Gross Proceeds

PETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...

6 months ago - GlobeNewsWire

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX 100  for the Prevention of Abdominal Colorectal Surgical Site Infections

8 months ago - GlobeNewsWire

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour Segal Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appo...

8 months ago - GlobeNewsWire

PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

PETACH TIKVA, Israel, Nov. 01, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...

8 months ago - GlobeNewsWire

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

PETACH TIKVA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...

9 months ago - GlobeNewsWire

PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...

9 months ago - GlobeNewsWire

PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform

Safety Profile of D-PLEX 100 and PLEX Platform Shown in Juvenile Animals for the First Time

9 months ago - GlobeNewsWire

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced ...

9 months ago - GlobeNewsWire

PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health

Successful Audit of the Company's State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ Globally Successful Audit of the Company's State-of-the-Art ...

9 months ago - GlobeNewsWire

PolyPid Announces Reverse Share Split

PETACH TIKVA, Israel, Sept. 20, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announces a...

9 months ago - GlobeNewsWire

PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀

Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale Completes a Substantial Requirement Toward the Planned Submission of D-PLEX 100 NDA and MAA Re...

9 months ago - GlobeNewsWire

PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial E valuating D-PLEX 100  for the Prevention of Abdominal Colorectal Surgical Site Infections

11 months ago - GlobeNewsWire

PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023

PETACH TIKVA, Israel, July 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced th...

11 months ago - GlobeNewsWire

PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections

Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide Range of Bacteria Tested, including Resistant Strains

1 year ago - GlobeNewsWire

PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections

Company Recently Reached Agreement with FDA on Design of Trial Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or t...

1 year ago - GlobeNewsWire

PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market

PETACH TIKVA, Israel, June 05, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it...

1 year ago - GlobeNewsWire